Blood type, ABO genetic variants, and ovarian cancer survival.

Blood type A and the A1 allele have been associated with increased ovarian cancer risk. With only two small studies published to date, evidence for an association between ABO blood type and ovarian cancer survival is limited.We conducted a retrospective cohort study of Tumor Registry confirmed ovari...

Full description

Bibliographic Details
Main Authors: Gabriella D Cozzi, Rebecca T Levinson, Hilary Toole, Malcolm-Robert Snyder, Angie Deng, Marta A Crispens, Dineo Khabele, Alicia Beeghly-Fadiel
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5407760?pdf=render
_version_ 1818854942524309504
author Gabriella D Cozzi
Rebecca T Levinson
Hilary Toole
Malcolm-Robert Snyder
Angie Deng
Marta A Crispens
Dineo Khabele
Alicia Beeghly-Fadiel
author_facet Gabriella D Cozzi
Rebecca T Levinson
Hilary Toole
Malcolm-Robert Snyder
Angie Deng
Marta A Crispens
Dineo Khabele
Alicia Beeghly-Fadiel
author_sort Gabriella D Cozzi
collection DOAJ
description Blood type A and the A1 allele have been associated with increased ovarian cancer risk. With only two small studies published to date, evidence for an association between ABO blood type and ovarian cancer survival is limited.We conducted a retrospective cohort study of Tumor Registry confirmed ovarian cancer cases from the Vanderbilt University Medical Center with blood type from linked laboratory reports and ABO variants from linked Illumina Exome BeadChip data. Associations with overall survival (OS) were quantified by hazard ratios (HR) and confidence intervals (CI) from proportional hazards regression models; covariates included age, race, stage, grade, histologic subtype, and year of diagnosis.ABO phenotype (N = 694) and/or genotype (N = 154) data were available for 713 predominantly Caucasian (89.3%) cases. In multivariable models, blood type A had significantly better OS compared to either O (HR: 0.75, 95% CI: 0.60-0.93) or all non-A (HR: 0.77, 95% CI: 0.63-0.94) cases. Similarly, missense rs1053878 minor allele carriers (A2) had better OS (HR: 0.50, 95% CI: 0.25-0.99). Among Caucasians, this phenotype association was strengthened, but the genotype association was attenuated; instead, four variants sharing moderate linkage disequilibrium with the O variant were associated with better OS (HR: 0.62, 95% CI: 0.39-0.99) in unadjusted models.Blood type A was significantly associated with longer ovarian cancer survival in the largest such study to date. This finding was supported by genetic analysis, which implicated the A2 allele, although O related variants also had suggestive associations. Further research on ABO and ovarian cancer survival is warranted.
first_indexed 2024-12-19T08:00:43Z
format Article
id doaj.art-0ca3f37cc6f74b5eaba23aa8fe4bdd46
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-19T08:00:43Z
publishDate 2017-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-0ca3f37cc6f74b5eaba23aa8fe4bdd462022-12-21T20:29:52ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01124e017511910.1371/journal.pone.0175119Blood type, ABO genetic variants, and ovarian cancer survival.Gabriella D CozziRebecca T LevinsonHilary TooleMalcolm-Robert SnyderAngie DengMarta A CrispensDineo KhabeleAlicia Beeghly-FadielBlood type A and the A1 allele have been associated with increased ovarian cancer risk. With only two small studies published to date, evidence for an association between ABO blood type and ovarian cancer survival is limited.We conducted a retrospective cohort study of Tumor Registry confirmed ovarian cancer cases from the Vanderbilt University Medical Center with blood type from linked laboratory reports and ABO variants from linked Illumina Exome BeadChip data. Associations with overall survival (OS) were quantified by hazard ratios (HR) and confidence intervals (CI) from proportional hazards regression models; covariates included age, race, stage, grade, histologic subtype, and year of diagnosis.ABO phenotype (N = 694) and/or genotype (N = 154) data were available for 713 predominantly Caucasian (89.3%) cases. In multivariable models, blood type A had significantly better OS compared to either O (HR: 0.75, 95% CI: 0.60-0.93) or all non-A (HR: 0.77, 95% CI: 0.63-0.94) cases. Similarly, missense rs1053878 minor allele carriers (A2) had better OS (HR: 0.50, 95% CI: 0.25-0.99). Among Caucasians, this phenotype association was strengthened, but the genotype association was attenuated; instead, four variants sharing moderate linkage disequilibrium with the O variant were associated with better OS (HR: 0.62, 95% CI: 0.39-0.99) in unadjusted models.Blood type A was significantly associated with longer ovarian cancer survival in the largest such study to date. This finding was supported by genetic analysis, which implicated the A2 allele, although O related variants also had suggestive associations. Further research on ABO and ovarian cancer survival is warranted.http://europepmc.org/articles/PMC5407760?pdf=render
spellingShingle Gabriella D Cozzi
Rebecca T Levinson
Hilary Toole
Malcolm-Robert Snyder
Angie Deng
Marta A Crispens
Dineo Khabele
Alicia Beeghly-Fadiel
Blood type, ABO genetic variants, and ovarian cancer survival.
PLoS ONE
title Blood type, ABO genetic variants, and ovarian cancer survival.
title_full Blood type, ABO genetic variants, and ovarian cancer survival.
title_fullStr Blood type, ABO genetic variants, and ovarian cancer survival.
title_full_unstemmed Blood type, ABO genetic variants, and ovarian cancer survival.
title_short Blood type, ABO genetic variants, and ovarian cancer survival.
title_sort blood type abo genetic variants and ovarian cancer survival
url http://europepmc.org/articles/PMC5407760?pdf=render
work_keys_str_mv AT gabrielladcozzi bloodtypeabogeneticvariantsandovariancancersurvival
AT rebeccatlevinson bloodtypeabogeneticvariantsandovariancancersurvival
AT hilarytoole bloodtypeabogeneticvariantsandovariancancersurvival
AT malcolmrobertsnyder bloodtypeabogeneticvariantsandovariancancersurvival
AT angiedeng bloodtypeabogeneticvariantsandovariancancersurvival
AT martaacrispens bloodtypeabogeneticvariantsandovariancancersurvival
AT dineokhabele bloodtypeabogeneticvariantsandovariancancersurvival
AT aliciabeeghlyfadiel bloodtypeabogeneticvariantsandovariancancersurvival